Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted inhaled medicines for severe respiratory conditions. The company's pipeline is primarily focused on treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Its lead product candidates, AP01 and AP02, are inhaled formulations of the established anti-fibrotic small-molecule drugs pirfenidone and nintedanib. These therapies are designed to improve efficacy and reduce systemic side effects by delivering medication directly to the lungs. Additionally, Avalyn is advancing AP03, a fixed-dose combination of both drugs. Operating from its headquarters in Boston, the company aims to establish a new standard of care for patients with rare lung diseases.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!